As of September 30, 2026, Star Lake Bioscience Co., Inc. Class A carries a market capitalization of 6.96B, placing it among publicly traded companies globally. Its enterprise value stands at 13.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.96B |
| Enterprise Value | 13.16B |
Star Lake Bioscience Co., Inc. Class A's next confirmed earnings release is scheduled for April 27, 2027.
| Earnings Date | 4/27/2027 |
As of September 30, 2026, Star Lake Bioscience Co., Inc. Class A has 1.66B shares outstanding.
| Shares Outstanding | 1.66B |
As of September 30, 2026, Star Lake Bioscience Co., Inc. Class A trades at a trailing price-to-earnings ratio of 353.95. The price-to-sales ratio is 0.43, and the price-to-book ratio stands at 0.91.
| PE Ratio | 353.95 |
| PS Ratio | 0.43 |
| PB Ratio | 0.91 |
| P/TBV Ratio | 1.00 |
These figures are as of September 30, 2026. The EV/Sales ratio of 0.82 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.16B versus a market cap of 6.96B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 0.82 |
As of September 30, 2026, Star Lake Bioscience Co., Inc. Class A maintains a current ratio of 0.77, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 98.88, indicating elevated leverage, while an interest coverage ratio of -0.14 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.77 |
| Quick Ratio | 0.22 |
| Debt / Equity | 98.88 |
| Debt / EBITDA | -639.37 |
| Interest Coverage | -0.14 |
Over the twelve months ended September 30, 2026, Star Lake Bioscience Co., Inc. Class A posted a return on equity (ROE) of 0.25, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.04, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.11, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.39, useful for judging operating efficiency across full business cycles. The company generates approximately 1.53M in revenue per employee across its workforce of 10,528.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.35 indicates how many times Star Lake Bioscience Co., Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 0.25 |
| Return on Assets (ROA) | 0.11 |
| Return on Invested Capital (ROIC) | -0.04 |
| Return on Capital Employed (ROCE) | 0.39 |
| Revenue Per Employee | 1.53M |
| Employee Count | 10,528.00 |
| Inventory Turnover | 6.35 |
Over the twelve months ended September 30, 2026, Star Lake Bioscience Co., Inc. Class A recorded 22.70M in income tax expense. That works out to an effective tax rate of 48.38, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 46.91M, leaving 19.67M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 22.70M |
| Effective Tax Rate | 48.38 |
As of the close on November 17, 2026, Star Lake Bioscience Co., Inc. Class A's stock has declined approximately 39.83% over the past 52 weeks. The 50-day moving average sits at 4.22, while the 200-day moving average is 5.49.
| 52-Week Price Change | -39.83% |
| 50-Day Moving Average | 4.22 |
| 200-Day Moving Average | 5.49 |
Over the twelve months ended September 30, 2026, Star Lake Bioscience Co., Inc. Class A generated 16.13B in revenue and converted that into 19.67M in net income, yielding earnings per share of 0.01. EBITDA reached -12.17M, while operating income came in at 166.46M.
| Revenue | 16.13B |
| Gross Profit | 1.51B |
| Operating Income | 166.46M |
| Pretax Income | 46.91M |
| Net Income | 19.67M |
| EBITDA | -12.17M |
| EBIT | -12.17M |
| Earnings Per Share (EPS) | 0.01 |
As of September 30, 2026, Star Lake Bioscience Co., Inc. Class A holds 1.82B in cash and equivalents against 7.78B in total debt, resulting in a net debt position of 5.42B. Total book value stands at 7.63B, with working capital of -1.89B providing operational flexibility.
| Cash & Cash Equivalents | 1.82B |
| Total Debt | 7.78B |
| Net Debt | 5.42B |
| Equity (Book Value) | 7.63B |
| Book Value Per Share | 4.60 |
| Working Capital | -1.89B |
These figures cover the twelve months ended September 30, 2026.
| Capital Expenditures | -1.96B |
Over the twelve months ended September 30, 2026, Star Lake Bioscience Co., Inc. Class A posted a gross margin of 9.35, reflecting its pricing power and cost economics. The operating margin of 1.03 and net profit margin of 0.12 provide insight into operational efficiency.
| Gross Margin | 9.35 |
| Operating Margin | 1.03 |
| Pretax Margin | 0.29 |
| Profit Margin | 0.12 |
| EBITDA Margin | -0.08 |
Over the twelve months ended September 30, 2026, Star Lake Bioscience Co., Inc. Class A paid dividends of 0.44 per share. The dividend payout ratio of 2,535.07 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -19.63, meaning Star Lake Bioscience Co., Inc. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Dividend Per Share | 0.44 |
| Payout Ratio | 2,535.07 |
| Shareholder Yield | -19.63 |
Star Lake Bioscience Co., Inc. Class A's most recent stock split took place on May 21, 2004 with a 5:8 split ratio.
| Last Split Date | 5/21/2004 |
| Split Ratio | 5:8 |
As of September 30, 2026, Star Lake Bioscience Co., Inc. Class A has an Altman Z-Score of 1.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.27 |
Already premium?